- Trial phase
- Phase 1b/2a
- Time to market
- Tagmokitug is in Phase 1b/2a development. Even with an expedited development path, a registrational trial would need to be designed, enrolled, and read out before any regulatory filing, which typically takes several years for a novel oncology asset.
- Why 4/10
- Tagmokitug is a Phase 1b/2a asset whose most recent catalyst (interim data on Oct 28, 2026) has already passed. The company announced a strategic prioritization plan on Nov 9, 2026 to pursue expedited development, but no specific dated binary catalyst (PDUFA, pivotal readout) is scheduled in the next ~12 months. Coherus has an approved product (LOQTORZI) generating revenue, so tagmokitug is not a make-or-break single asset. Impact score of 4 reflects a mid-stage pipeline drug with no imminent hard catalyst.
The next catalyst for tagmokitug is further clinical data from the TREGCHECK program, potentially in H1 2027, as Coherus pursues an expedited development path in esophageal cancer. The October 2026 interim data (75% ORR in 1L ESCC) was encouraging but the stock fell 23% on the day, suggesting the market wanted larger sample sizes or clearer registration path details. Watch for the company to outline specific registrational trial plans and timelines in upcoming investor events.
Price Chart
Executive Summary
Tagmokitug (CHS-114) is Coherus Oncology's investigational cytolytic CCR8 antibody designed to deplete immunosuppressive regulatory T cells in the tumor microenvironment. On October 28, 2026, Coherus reported interim Phase 1b data from the TREGCHECK program showing a 75% confirmed overall response rate in first-line esophageal squamous cell carcinoma (ESCC) and 100% in PD-L1-positive patients, with activity across five tumor types. Despite the strong efficacy signal, CHRS stock fell 23% the following day, suggesting the market wanted larger sample sizes or clearer registration plans. On November 9, 2026, Coherus announced a strategic prioritization plan focusing all development efforts on tagmokitug/toripalimab for esophageal cancer with expedited development. The drug is still in early-to-mid stage development (Phase 1b/2a) with no specific pivotal trial or regulatory filing date set, making it a high-risk/high-reward pipeline asset for a company with a ~$150M market cap trading near its 52-week low.
How It Works
Tagmokitug is an antibody designed to seek out and destroy a specific type of immune cell called regulatory T cells (Tregs) that carry a protein called CCR8 on their surface. In many cancers, these CCR8-positive Tregs accumulate inside tumors and act as brakes on the immune system, preventing it from attacking the cancer. By killing these cells, tagmokitug releases the brakes and allows the immune system to fight the tumor more effectively. It is given in combination with toripalimab (a PD-1 checkpoint inhibitor) and sometimes chemotherapy.
Trial Status
Tagmokitug is being evaluated in the TREGCHECK development program, a Phase 1b/2a study (TREGCHECK 102) in combination with toripalimab and/or chemotherapy across multiple advanced solid tumors. Interim data from October 28, 2026 showed results from over 120 patients across five indications, with a focus on esophageal squamous cell carcinoma (ESCC). The company announced on November 9, 2026 a strategic prioritization plan to focus on tagmokitug/toripalimab for esophageal cancer with expedited development.
The Two-Sided Case
Upcoming Catalysts
- Further mature clinical data from the TREGCHECK program (potentially H1 2027)
- Details on registrational trial design and expedited development path for tagmokitug in esophageal cancer
- Potential presentation at major medical conferences (ASCO, ESMO, SITC)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Coherus Oncology, Inc. PRESS-RELEASE CHRS ·Originating report